Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 13668-103

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 13668-103). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Torrent Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 01

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 02

This appears to be a table showing ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale) changes from baseline in patients receiving either Donepezil Hydrochloride Tablets (at doses of 5 mg/day or 10 mg/day) or a Placebo, at 6, 12, and 18 weeks of drug treatment. The table also indicates the occurrence of clinical improvement or decline in patients.*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 03

The document appears to be a graph or a chart showing the cumulative percentage of patients under the treatment of Donepezil Hydrochloride Tablets. The y-axis shows the percentage of patients (ranging from 0 to 100) while the x-axis shows the change in ADAS-cog (ranging from -15 to 15). The graph includes three categories: 10 mg/day Donepezil Hydrochloride Tablets, 5 mg/day Donepezil Hydrochloride Tablets, and placebo. The categories are further divided into four columns showing the percentage of patients having no change, 4 points, 7 points, and more.*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 04

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 05

This text displays a chart showing the ADAS-cog change from baseline over weeks of drug treatment with Donepezil hydrochloride tablets 10mg/day, Donepezil hydrochloride tablets 5mg/day, and a placebo. It also indicates clinical improvement or decline.*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 06

This is a table that shows the cumulative percentage of patients who have had a change in their ADAS-COG score after taking Donepezil Hydrochloride Tablets at different doses of 5mg/day and 10mg/day, as well as a placebo group. The changes are categorized by treatment groups, with either 7, 4 or 0 points, and indicate whether there was improvement, no change, or a decline in cognitive function. The table also shows the change from baseline in ADAS-COG scores over a period of 15 weeks.*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 07

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 08

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 09

The text describes a chart or graph that shows the cumulative percentage of patients. The chart or graph appears to compare the effects of Donepezil Hydrochloride Tablets (10 mg/day) with the effects of a placebo. The chart or graph also includes data on SIB Change from Baseline.*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 10

This is a figure showing the change in ADCS-ADL-Severe score over 6 months of treatment for patients taking Donepezil Hydrochloride Tablets 10 mg/day versus those on placebo. The x-axis represents the months of drug treatment and the y-axis represents the change from baseline in the ADCS-ADL-Severe score. The plot shows that patients on Donepezil had a greater clinical improvement compared to those on placebo, as indicated by the positive change from baseline in their score. Those on placebo experienced a decline in their score.*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 11

This is a graph indicating the Cumulative Percentage of Patients, comparing the effectiveness of Donepezil Hydrochloride Tablets and Placebo, based on the ADCS-ADL Change from Baseline. The x-axis shows the percentage values, while the y-axis lists Donepezil Hydrochloride Tablets and Placebo.*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 12

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 13

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 14

This is a description of a medication containing 5mg of Donepezil Hydrochloride. The tablets are coated with a film and are meant to be stored between 68-77°F. The proper dosage is not provided in the text, but can be found on the accompanying prescription information. The medication should be dispensed in a moisture-resistant container with an airtight closure. The text also contains information about the manufacturer and the product code.*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 15

Each film-coated tablet contains 10mg donepezil hydrochloride, USP. It should be stored at 20° to 25°C (68° to 77°F) with excursions permitted at 15° to 30°C (59° to 86°F). The tablets need to be dispensed in a tight, light-resistant container with a child-resistant closure. The usual dosage should be followed carefully, and the prescribing information should be consulted. This product is made by Torrent Pharmaceuticals LTD and comes in a pack of 30 tablets. The details for dispensing the medication are provided in the accompanying patient's information sheet. This product is available only by prescription.*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 16

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.